Oculopharyngeal muscular dystrophy (OPMD) belongs to the group of protein aggregation disorders and is caused by extensions of the N-terminal polyalanine stretch of the nuclear poly(A)-binding protein 1 (PABPN1). The presence of PABPN1-containing intranuclear aggregates in skeletal muscle is unique for OPMD and is also observed in transgenic mouse and cell models for OPMD. These models consistently support a direct role for the protein aggregation in OPMD pathogenesis. We have isolated and characterized a diverse panel of single-domain antibody reagents (VHH) recognizing different epitopes in PABPN1. The antibody reagents specifically detect endogenous PABPN1 in cell lysates on Western blot and label PABPN1 in cultured cells and muscle sections. When expressed intracellularly as intrabodies in a cellular model for OPMD, aggregation of PABPN1 was prevented in a dose dependent manner. More importantly yet, these intrabodies could also reduce the presence of already existing aggregates. Given the domain-specificity of VHH-mediated aggregation interference, this approach at least allows the definition of the nucleation-kernel in aggregation-prone proteins, thus facilitating etiological insight in this and other protein aggregation disorders, and ultimately it may well provide useful therapeutic agents.
Introduction
Oculopharyngeal muscular dystrophy (OPMD, MIM164300) is a late-onset disease, clinically characterized by slow progressive ptosis, dysphagia and limb girdle weakness (1) . OPMD is usually inherited as an autosomal dominant trait and caused by a trinucleotide repeat expansion in the coding region of the nuclear poly(A)-binding protein 1 (PABPN1) gene (2) . The alanine stretch that is encoded by this trinucleotide sequence contains 10 alanines in the non-affected protein, but is expanded to 12-17 alanines in the mutant protein in autosomal dominant OPMD.
PABPN1 is ubiquitously expressed and is involved in poly(A)-tail synthesis and poly(A)-tail lengthcontrol (3) . One of the pathological hallmarks of OPMD is the presence of PABPN1-containing fibril-like aggregates in 2-5% of myonuclei in affected muscle (4) (5) (6) . The roles of the formation of the intranuclear inclusions in the progression of OPMD are poorly understood (1, 7, 8) .
Recently, a doxycyline-based treatment for OMPD was proposed based on animal studies with transgenic mice (8) . These mice develop OPMD-like muscle defects and also show intranuclear aggregation of mutant PABPN1. Upon doxycycline treatment, the muscle defects improved and aggregate formation was reduced, suggesting a direct role for protein aggregation in OPMD pathogenesis. PABPN1 aggregation has also been studied in cellular models using transient expression of wild type and expanded PABPN1. Aggregate formation was inhibited in these cellular models for OPMD by doxycycline, Congo red and over-expressed chaperones (9-11). These studies also resulted in increasing knowledge of the toxicity of the intranuclear inclusions (12) , proteins (9, 13, 14) and nucleic acids included in the formed inclusions, and the dynamic nature of the intranuclear inclusions (14) . For example, it was shown that reduction of aggregate formation leads to increased cell survival (11) .
Despite the effectiveness of some of these aggregation reducing agents, none of them is specific for PABPN1 aggregation. Instead, many of these agents were tested in analogy to other protein aggregation conditions and operate through poorly understood mechanisms. In parallel, also antigen-specific approaches have been applied to reduce aggregation. By intracellular expression of single-chain Fv (scFv) (15) The advantage of single-domain antibody reagents over the approaches just described lies in their single domain character, ease of generation, small size and stability (17) . The immediate availability of their sequence make these antibody fragments amenable to genetic modification and intracellular expression using conventional expression vectors. This also facilitates their structural and functional analysis. Thus, singledomain antibodies were used to immunomodulate several antigens (18) (19) (20) .
We aimed at isolating single-domain antibody reagents against PABPN1 to investigate whether we could inhibit intranuclear inclusion formation in OPMD cell models. Using a combination of selections for single-domain antibody reagents, we obtained different sets of antibody reagents. By intracellular expression of some of these antibody reagents we were able to inhibit aggregation in situ in a dose dependent manner.
Experiments with serial expression of mutant PABPN1 and PABPN1-specific intrabody, indicate that even existing aggregates could be cleared.
Results

Antibody selections
To isolate antibody reagents against PABPN1 two successive phage selection rounds were employed against E. coli-produced and affinity purified full-length human PABPN1. In pilot experiments, we found that a combination of capturing the antigen in the first round (by its T7 tag) followed by direct immobilization in the second round, yields the most diverse set of binders (Verheesen, P. et al, in preparation). To ensure that different epitopes were recognized by the selected antibody reagents we performed several epitope-masking selections in which antibody reagents obtained in earlier selection rounds were used to capture PABPN1.
The enriched sub-libraries were screened for monoclonal antibody reagents with specificity for PABPN1.
From the different selections a total of 6 different antibody reagents were identified with affinities for PABPN1 between 5 and 57 nM (data not shown). 
Epitope mapping
Three selected antibody reagents were further characterized by epitope mapping with Western blotting using a panel of truncated recombinant PABPN1 proteins. All mapped to epitopes within the aminoterminal 155 amino-acids. One of the VHH, coded 3F5, obviously showed the strongest signals on Western blot. As this antibody reagent also exhibited the highest affinity (5 nM) for both the recombinant produced PABPN1 and native PABPN1 we continued with this antibody reagent for a more detailed epitope mapping. From these epitope mappings (Fig. 1) we conclude that the epitope for 3F5 is situated between amino acids 113 and 133, which largely overlaps with the part of PABPN1 that was predicted to form an amphiphatic α-helical or coiled-coil domain (amino acids L119-Q147) (21) . Using a series of different point mutants of PABPN1, we could demonstrate that residues at position 126, 129 and 131 are essential for binding of the antibody reagent ( Fig. 1) .
Detection of endogenous PABPN1
3F5 was subsequently used for Western blotting with cytosolic and nuclear fractions from HeLa cells (Fig   2a) . A single band with an expected molecular weight of 50kDa was specifically detected in the nuclear protein fraction. Next, in two independent cell lines, HeLa and COS-1 cells, we observed an expected predominant nuclear staining with denser fluorescent signal in a speckle-like pattern by immunofluorescence microscopy ( Fig. 2b-e) (22) . In addition to cultured cells, cryosections of control human muscle were stained with 3F5 as well ( Fig. 1f-g ). Nuclear localization with accumulation in a speckle-like pattern was observed, indicating successful detection of PABPN1 in muscle.
Cell model for PABPN1 aggregation
To discriminate between endogenous and over-expressed mutant PABPN1 we transfected mPABPN1-ala17 in fusion with the vesicular stomatitis virus glycoprotein (VSV) tag in COS-1 and HeLa cells. Intranuclear aggregation of PABPN1 was observed (Fig. 3a, b) . Incubation of these cells with fluorescent oligo(dT), anti-HSP70 and anti-ubiquitin antibodies showed that poly(A)-RNA, HSP70 and ubiquitin were present in the aggregates (data not shown), as has been reported previously (4, 9).
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We assessed whether transfected mPABPN1-ala17 was localized differently compared to endogenous PABPN1. To this end, HeLa cells were transfected with mPABPN1-ala17 and the transfected mPABPN1-ala17 was visualized by incubation with anti-VSV antibodies while total PABPN1 was visualized with 3F5. No differences in localization of both signals were observed.
Prevention of aggregation by intrabody 3F5
The effect of intracellular expression of 3F5 was investigated in cellular PABPN1 aggregation models.
Intrabody 3F5 was transfected in fusion with a nuclear localization signal (NLS) and green fluorescent protein (GFP) (3F5-NLS-GFP) in COS-1 and HeLa cells. The GFP signal was exclusively observed in the nucleus indicating both a successful expression of intrabody and its targeting to the nucleus (Fig. 3c, d ).
Subsequently, 3F5-NLS-GFP was co-transfected with mPABPN1-ala17 ( Fig. 3e-g ) in different ratios. In a dose-dependent manner in which mPABPN1-ala17 was kept constant and increasing concentrations of 3F5-NLS-GFP, the intrabody could completely prevent aggregation (Fig. 4) . The expression levels of mutant PABPN1 and intrabody 3F5 or NLS-GFP control were analyzed by Western blotting (Fig. 5) . This showed that expression of the intrabody did not affect the expression levels of its antigen mPABPN1-ala17.
To explore putative cytotoxic effects of the intracellular expression of 3F5, cells were singly transfected with the intrabody construct and analysed at different time points by Western blotting. A gradual increase in intrabody expression was observed in time without a detectable effect on endogenous PABPN1 levels. Cells that were singly transfected with the intrabody construct were also microscopically investigated.
PABPN1 was labelled with one of the selected antibody reagents which recognizes a distinct epitope from the binding place of 3F5. The PABPN1 localization in intrabody expressing cells was indistinguishable from its localization in non-transfected cells. With a cell proliferation assay, the metabolic activity in intrabodytransfected cells was compared to non-transfected cells. No difference in metabolic activity was observed between these cells. Therefore, intracellular expression of 3F5 did not cause any detectable cytotoxic effects based on analysis of endogenous antigen levels and localization, and cell viability.
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Clearing of existing aggregates
To investigate whether pre-existing aggregates can be cleared with our intrabody we performed consecutive transfections with mPABPN1-ala17 and intrabody 3F5 in COS-1 and HeLa cells. Twenty-four hours after transfection, 38(±4)% of HeLa cells and 33(±8)% of COS-1 cells showed intranuclear aggregates. Intrabody 3F5, control intrabody or NLS-GFP control were transfected 24 hrs after transfection of mPABPN1-ala17. To date, the mechanism of specific development of muscle defects in OPMD remains unclear but a direct role for the protein aggregation in OPMD pathogenesis has been suggested. On average 2-5% of the nuclei in affected OPMD muscle contain visible intranuclear inclusions and in some cases intranuclear inclusions appear mostly in myonuclei of affected tissue (1, 23) . Moreover, homozygotes for OPMD show a more severe phenotype and have significantly more intranuclear inclusions (24) . Aggregates of mutant PABPN1 are present in post-mitotic long living myonuclei of OPMD patients (4-6), which may indicate a relationship between the differentiation state of the cell and the appearance of detectable inclusions (1) . It was shown that mutant PABPN1 aggregates contain high concentrations of poly(A)-RNA and it was suggested that poly(A)-RNA entrapment in aggregates may play a role in OPMD pathogenesis (4). The 8 muscle-specific phenotype may be further explained by sequestration of ski-interacting protein (SKIP) in the aggregates, as it is known that PABPN1 and SKIP synergistically activate MyoD (25). Although the exact pathological mechanism underlying OPMD is only partly understood, cellular and animal models studies of OPMD are consistent with the view that the aggregation process, and more specifically early oligomeric or microaggregate mutant proteins, are toxic (1, 4, 9, 12) . The selected antibody reagents may thus prove useful in further studies of the role of PABPN1 aggregation in OPMD pathogenesis.
Currently, over-expression of mPABPN1 in COS-1 and HeLa cells are the only cellular reporter systems that have been demonstrated to show mPABPN1-aggregation that leads to cell death (11) . Inhibition of aggregate formation with chaperones, doxycycline and Congo red has been described (9-11). However, these chaperones and chemicals are not specific for PABPN1 aggregates but rather recognize a large number of misfolded or aggregated proteins and may thus have undesired side-effects. In contrast, antibodies that specifically bind their target can be used for specific intervention. We have therefore selected a PABPN1-specific monoclonal antibody reagent for which we show that we are able to prevent aggregate formation by mutant PABPN1 in a dose-dependent manner. Intracellular expression of this antibody reagent did not yield any detectable deleterious side effects as assayed by normal antigen levels, localization or cell viability. The observation that endogenous and transient PABPN1 protein levels in transfected cells are not influenced by the expression of PABPN1-specific intrabodies indicates that reduction of aggregate formation by the intrabody is a direct effect of the intrabody and not the level of the mutant protein. This concerns a very specific interaction, as intrabodies against other epitopes on PABPN1 were not able to prevent aggregate formation (data not shown). Potential oligomerization domains have been identified in PABPN1 that were shown to play a role in aggregation (12) . Binding of 3F5 to these or yet unidentified regions may prevent aggregation by shielding off these regions for other interactions similar as was shown with deletion constructs (12) .
In consecutive transfections of mPABPN1 and 3F5 we showed that the intrabody not only prevents aggregation, but also clears already existing aggregates. Three independent transfection experiments in two different cell lines showed a significant reduction of aggregate-containing cells when a surplus of 3F5 was expressed in cells in which aggregates were already formed (p<0.05). This observation could suggest a 9 dynamic nature of the aggregates formed in this cell model consistent with earlier photobleaching experiments that revealed that both normal and expanded PABPN1 molecules are not irreversibly sequestered into aggregates and with the presence of reversible non-pathological PABPN1 aggregates in normal magnocellular neurosecretory neurons of the rat hypothalamus (7, 14) . Furthermore, in a transgenic mouse model for OPMD it was demonstrated that aggregate reducing agents delayed the muscle pathology (8) . Therefore, it is feasible that in OPMD patients, reagents that act on the equilibrium between soluble and oligomeric or aggregated PABPN1, may also reduce already formed aggregates.
In conclusion, we have shown that single-domain antibody reagents from Camelidae can highly selectively block or revert pathological processes. Efficient in vivo immunomodulation by single-domain antibody reagents was recently reported in plants (18) . Therefore, in further studies we will improve efficient delivery of the single-domain antibody reagents in cells of affected OPMD tissue to evaluate whether also in affected tissue, 3F5 will have preventive and curative properties.
Material and Methods
Antibody selections
The human cDNA sequence of PABPN1 was cloned into the prokaryotic expression vector pET28a (Novagen). Recombinant protein was produced in BL21(DE3)-RIL E. coli (Stratagene). The protein was purified by means of the attached His-tag using TALON (BD Biosciences). Two rounds of selection were performed with a large (5*10 9 ) non-immune llama single-domain antibody reagent library (kindly provided by Unilever Research Vlaardingen, The Netherlands), using standard procedures (26) . Briefly, with differences as described: monoclonal antibody against the T7-tag (Novagen) (10µg/ml in PBS (137mM NaCl, 2.7mM KCl, 8mM Na 2 HPO 4 , 1.5mM KH 2 PO 4 )) was coated to maxisorp 96-well plates (Nunc). After blocking with 4%skimmed milk in PBS (4%MPBS) the purified T7-tagged PABPN1 (10µg/ml in 0.1%MPBS) was captured. 10 11 phages (in 2%MPBS, 1%bovine serum albumin (BSA), 10%normal mouse serum (NMS)) were added and incubated for 90min. at room temperature (RT). After extensive washing with 0.05%Tween-20 in PBS (PBST) and PBS, bound phages were eluted with 100mM Triethylamine (TEA) for 10min. at RT. Phages were prepared for the second selection round as described. Bound phages were eluted with high pH. These phages were multiplied and used for a second selection round. This second selection round was performed similar to round 1 except that PABPN1 (10µg/ml in PBS) was directly coated to maxisorp plates and 10 9 phages were used. For epitope-masking selections (27, 28) against PABPN1, 10µg/ml VHH3F5 was coated to polystyrene plates and bovine PABPN1 from calf thymus (kindly provided by Antje Ostareck-Lederer, Martin-Luther-University Halle, Germany) was captured as described before. After the second selection round, single colonies were picked in 96-well plates and cmyc-tagged VHH (VHH-myc) were produced by overnight induction in 96-well plates. Culture supernatants
containing VHH-myc were tested with ELISA for binding to directly coated PABPN1 (10µg/ml in PBS).
VHH-myc were detected with mouse anti-c-myc antibodies (kind gift from P.W. Hermans, Biotechnology
Application Centre, The Netherlands) and anti-mouse peroxidase-conjugated antibodies (Jackson). Singlecolony PCR was performed as described, PCR fragments were cut with HinfI (New England Biolabs) and analyzed on 2%agarose gels.
Epitope mapping
The following PABPN1 domains were PCR-amplified from the full-length PABPN1 cDNA and cloned in a 
Affinity measurements
Association and dissociation constants (k on and k off , respectively) for the binding of 3F5 to PABPN1 were measured using a Biacore3000 (Biacore) and covalently coupled recombinant PABPN1 and 3F5 to a CM5 sensor chip. Affinities were calculated using Biacore evaluation software.
Cell culture and immunofluorescent labeling
HeLa and COS-1 cells were cultured according to standard protocols. Cells were grown on coverslips for 24h, washed with PBS and fixed with 4%formaldehyde in PBS for 15min. at RT. Triton X-100 was added to a final concentration of 0.1% and cells were permeabilized for 15min. at RT. Cells were blocked with 100mM glycine in PBS and 1%BSA in PBS both for 15min. at RT and incubated with 3F5 (1µg/ml in 1%BSA/PBS) for 90min. at RT. VHH were detected with anti-c-myc monoclonal antibody and Alexa Fluor 488-labeled anti-mouse antibody (Molecular Probes) in 1%BSA/PBS, each for 1h. Cells were incubated with 0.2µg/ml DAPI (Roche) together with the last antibody incubation to visualize nuclei. 6µm crosssections from a control human muscle biopsy were air-dried for 30min., fixed and labeled with 3F5 as described for cultured cells. 
Transfections and quantification of aggregates
Cell proliferation assay
Possible toxic effects of the transient expression of our mPABPN1 and intrabody constructs were cell proliferation assay that discriminates between dead and living cells based on their metabolic activity.
MTT was dissolved in culture medium in 1mg/ml concentration.
Western blotting
Cytosolic and nuclear fractions of HeLa cells were prepared as described (31) , loaded on 12%SDS-polyacrylamide (SDS-PAGE) gels and transferred to PVDF Western blotting membranes (Roche).
Membranes were incubated with 3F5 (1µg/ml in 2%MPBS) overnight at 4ºC, followed by incubation with an NLS-sequence and GFP. The intrabody was produced and localized in cell nuclei 24h after transfection. (e-g), mPABPN1-ala17 and 3F5 were co-transfected in HeLa cells. mPABPN1-ala17 and the intrabody were detected in cell nuclei of co-transfected cells. Decreased aggregation was observed with co-expression of 3F5 compared to control intrabody or NLS-GFP 48h after transfection (Fig. 4) . (h-j) mPABPN1-ala17 and NLS-GFP were co-transfected in HeLa cells. mPABPN1-ala17 and NLS-GFP were detected in the cell nuclei. Intranuclear aggregates were observed 48h after transfection. Bar = 10µm. 
